Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox versus deferoxamine in transfusional iron overload in sickle cell disease
ISRCTN05896089Phase 2Completed
- Sponsor
- Novartis
- Start
- Jan 2004
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, open-label trial in transfusional hemosiderosis and sickle cell disease (SCD) comparing Deferasirox with Deferoxamine (2 arms). Primary endpoints: Safety laboratory assessments, Physical safety assessments and 1 more. Started Jan 2004; status: completed.
02
Drugs
deferasiroxdeferoxamine
03
Conditions
transfusional hemosiderosissickle cell disease (SCD)
Beyond the preview
Go deeper on ISRCTN05896089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN05896089.